Observational studyThe Journal of antimicrobial chemotherapy2024
A microbiological and genomic perspective of globally collected Escherichia coli from adults hospitalized with invasive E. coli disease.
Observational study in The Journal of antimicrobial chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Lineage-aware comparison of extended-spectrumMicrobial genomics · 2026Article
- Global survey of extraintestinal pathogenic Escherichia coli identifies stable serogroup-virulence-resistance linkages.Genome medicine · 2026Article
- Genome-based source attribution using a One HealthMicrobial genomics · 2026Article
- Molecular epidemiology and structural diversity of O101/O162 O-antigen variants among Escherichia coli bacteremia isolates.Scientific reports · 2026Article
- "Super Sandwich" Assay Using Phenylboronic Acid for the Detection ofMicroorganisms · 2025Article
- The possibility of Escherichia coli transmission from pregnant women to the neonates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Current Scientific Advances in Vaccines Against UTIs: Challenges and Prospects.Microorganisms · 2025Review
- Antimicrobial resistance trends of Escherichia coli and Staphylococcus aureus isolated from clinical blood cultures in Namibia: a nine-year (2011-2019) retrospective study.BMC infectious diseases · 2025Article
- Overstory plant canopy and plant organ-age enhance the survival capacity and the medicinal properties of Tephrosia apollinea in Fujairah.Scientific reports · 2025Article
- A retrospective global study of the prevalence of O-serotypes of invasiveEpidemiology and infection · 2025Observational
- High diversity of Escherichia coli causing invasive disease in neonates in Malawi poses challenges for O-antigen based vaccine approach.Communications medicine · 2025Article
- A Bioconjugate Vaccine Against Extra-Intestinal PathogenicVaccines · 2025Article
- Sodium-glucose co-transporter 2 inhibitors use and the risks of genital and urinary tract infection: What should we know?Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectivesEscherichia coli can cause infections in the urinary tract and in normally sterile body sites leading to invasive E. coli disease (IED), including bacteraemia and sepsis, with older populations at increased risk. We aimed to estimate the theoretical coverage rate by the ExPEC4V and 9V vaccine candidates. In addition, we aimed at better understanding the diversity of E. coli isolates, including their genetic and phenotypic antimicrobial resistance (AMR), sequence types (STs), O-serotypes and the bacterial population structure.
methodsBlood and urine culture E. coli isolates (n = 304) were collected from hospitalized patients ≥60 years (n = 238) with IED during a multicentric, observational study across three continents. All isolates were tested for antimicrobial susceptibility, O-serotyped, whole-genome sequenced and bioinformatically analysed.
resultsA large diversity of STs and of O-serotypes were identified across all centres, with O25b-ST131, O6-ST73 and O1-ST95 being the most prevalent types. A total of 45.4% and 64.7% of all isolates were found to have an O-serotype covered by the ExPEC4V and ExPEC9V vaccine candidates, respectively. The overall frequency of MDR was 37.4% and ST131 was predominant among MDR isolates. Low in-patient genetic variability was observed in cases where multiple isolates were collected from the same patient.
conclusionsOur results highlight the predominance of MDR O25b-ST131 E. coli isolates across diverse geographic areas. These findings provide further baseline data on the theoretical coverage of novel vaccines targeting E. coli associated with IED in older adults and their associated AMR levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.